Author

RA Railkar

Observed name: R. A. Railkar

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), Mayo Clinic, Baylor College of Medicine, Yonsei University, Asan Medical Center, Dana-Farber Cancer Institute, Mayo Clinic in Florida

OpenAlex ID: A5037510026

Leveraging a Clinical Phase Ib Proof‐of‐Concept Study for the GPR40 Agonist MK‐8666 in Patients With Type 2 Diabetes for Model‐Informed Phase II Dose Selection

2017 · AW Krug, P Vaddady, et al. · Clinical and Translational Science · 16

An accessible pharmacodynamic transcriptional biomarker for notch target engagement

2016 · KQ Tanis, AA Podtelezhnikov, et al. · Clinical Pharmacology & Therapeutics · 4

Impact of a Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) L1 Virus-like Particle Vaccine in a Sexually Active Population of North American Women

2008 · E Barr, CK Gause, et al. · Journal of Lower Genital Tract Disease · 3

Abstract P4-01-11: Limits of [18F]-FLT PET as a clinical biomarker of proliferation in breast cancer

2013 · EV Schmidt, S Blackman, et al. · Cancer Research · 1

Correlation between FLT-PET and Ki-67 change in breast cancer during neoadjuvant chemotherapy.

2010 · S. C. Blackman, R. A. Railkar, et al. · Journal of Clinical Oncology

Works count: 5

Citation count: 24

H-index: 3

I10-index: 1